Tsutomu Shimada

List of Publications by Year
in descending order

138 papers	11,945 citations	20759 60 h-index	26548 107 g-index
138 all docs	138 docs citations	138 times ranked	7489 citing authors

#	Article	IF	Citations
1	Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 1991, 4, 391-407.	1.7	1,003
2	Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1. Cancer Science, 2004, 95, 1-6.	1.7	640
3	Xenobiotic-Metabolizing Enzymes Involved in Activation and Detoxification of Carcinogenic Polycyclic Aromatic Hydrocarbons. Drug Metabolism and Pharmacokinetics, 2006, 21, 257-276.	1.1	492
4	Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis, 1992, 13, 1789-1794.	1.3	369
5	Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes. Archives of Biochemistry and Biophysics, 1997, 346, 161-169.	1.4	283
6	Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 462-465.	3.3	273
7	Activation and detoxication of aflatoxin B1. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 402, 121-128.	0.4	271
8	Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis, 1999, 20, 1607-1614.	1.3	236
9	Activation of procarcinogens by human cytochrome P450 enzymes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 400, 201-213.	0.4	229
10	Roles of NADPH-P450 Reductase and Apo- and Holo-Cytochrome b5 on Xenobiotic Oxidations Catalyzed by 12 Recombinant Human Cytochrome P450s Expressed in Membranes of Escherichia coli. Protein Expression and Purification, 2002, 24, 329-337.	0.6	224
11	SOS-inducing activity of chemical carcinogens and mutagens in Salmonella typhimurium TA1535/pSK1002: examination with 151 chemicals. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1987, 192, 239-246.	1.2	221
12	Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry, 1990, 29, 11280-11292.	1.2	215
13	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology, 1999, 73, 65-70.	1.9	209
14	Oxidation of Aflatoxin B1 by Bacterial Recombinant Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 1995, 8, 218-225.	1.7	208
15	Selectivity of Polycyclic Inhibitors for Human Cytochrome P450s 1A1, 1A2, and 1B1. Chemical Research in Toxicology, 1998, 11, 1048-1056.	1.7	198
16	Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis, 2002, 23, 1199-1207.	1.3	197
17	Roles of Cytochromes P450 1A2 and 3A4 in the Oxidation of Estradiol and Estrone in Human Liver Microsomes. Chemical Research in Toxicology, 1998, 11, 659-665.	1.7	171
18	Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics and Genomics, 2000, 10, 25-33.	5.7	170

#	Article	IF	Citations
19	Inhibition of Human Cytochrome P450 1A1-, 1A2-, and 1B1-Mediated Activation of Procarcinogens to Genotoxic Metabolites by Polycyclic Aromatic Hydrocarbons. Chemical Research in Toxicology, 2006, 19, 288-294.	1.7	169
20	Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Archives of Toxicology, 1997, 71, 401-408.	1.9	166
21	Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4. Journal of Biological Chemistry, 1996, 271, 27438-27444.	1.6	159
22	Comparative Studies on the Catalytic Roles of Cytochrome P450 2C9 and Its Cys- and Leu-Variants in the Oxidation of Warfarin, Flurbiprofen, and Diclofenac by Human Liver Microsomes. Biochemical Pharmacology, 1998, 56, 243-251.	2.0	153
23	Metabolism of Benzo[a]pyrene to trans-7,8-Dihydroxy-7,8-dihydrobenzo[a]pyrene by Recombinant Human Cytochrome P450 1B1 and Purified Liver Epoxide Hydrolase. Chemical Research in Toxicology, 1999, 12, 623-629.	1.7	151
24	Binding of Two Flaviolin Substrate Molecules, Oxidative Coupling, and Crystal Structure of Streptomyces coelicolor A3(2) Cytochrome P450 158A2. Journal of Biological Chemistry, 2005, 280, 11599-11607.	1.6	142
25	Roles of Divalent Metal Ions in Oxidations Catalyzed by Recombinant Cytochrome P450 3A4 and Replacement of NADPH-Cytochrome P450 Reductase with Other Flavoproteins, Ferredoxin, and Oxygen Surrogates. Biochemistry, 1995, 34, 8380-8389.	1.2	137
26	Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003, 523-524, 173-182.	0.4	135
27	Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes. Archives of Biochemistry and Biophysics, 1996, 325, 174-182.	1.4	130
28	Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4???-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics and Genomics, 1997, 7, 103-113.	5.7	130
29	Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochemical Pharmacology, 1997, 54, 1195-1203.	2.0	129
30	Reconstitution of Recombinant Cytochrome P450 2C10(2C9) and Comparison with Cytochrome P450 3A4 and Other Forms: Effects of Cytochrome P450â€“P450 and Cytochrome P450â€“b5Interactions. Archives of Biochemistry and Biophysics, 1997, 342, 329-337.	1.4	127
31	Role of phospholipids in reconstituted cytochrome P 450 3A form and mechanism of their activation of catalytic activity. Biochemistry, 1992, 31, 6063-6069.	1.2	126
32	Molecular Cloning of a Novel Human Collectin from Liver (CL-L1). Journal of Biological Chemistry, 1999, 274, 13681-13689.	1.6	126
33	Human cytochrome P-450 enzymes. Life Sciences, 1992, 50, 1471-1478.	2.0	119
34	Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica, 1996, 26, 395-403.	0.5	119
35	Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochemical Pharmacology, 1994, 47, 727-735.	2.0	117
36	Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chemical Research in Toxicology, 1992, 5, 202-210.	1.7	115

#	Article	IF	Citations
37	Tissue-specific induction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of arylhydrocarbon receptor gene. Toxicology and Applied Pharmacology, 2003, 187, 1-10.	1.3	115
38	Structureâ^'Function Relationships of Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 Flavonoid Derivatives. Chemical Research in Toxicology, 2010, 23, 1921-1935.	1.7	115
39	Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1. Molecular Pharmacology, 2006, 69, 2007-2014.	1.0	96
40	Recombinant Human Cytochrome P450 1B1 Expression inEscherichia coli. Archives of Biochemistry and Biophysics, 1998, 357, 111-120.	1.4	95
41	Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylainine to products genotoxic in an acetyltransferaseâ€“overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis, 1992, 13, 979-985.	1.3	94
42	New Applications of Bacterial Systems to Problems in Toxicology. Critical Reviews in Toxicology, 1996, 26, 551-583.	1.9	94
43	Stimulation of Cytochrome P450 Reactions by Apo-cytochromeb 5. Journal of Biological Chemistry, 2001, 276, 30885-30891.	1.6	94
44	7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochemical Pharmacology, 1996, 51, 313-319.	2.0	88
45	Metabolism of (+)- and (â^')-Limonenes to Respective Carveols and Perillyl Alcohols by CYP2C9 and CYP2C19 in Human Liver Microsomes. Drug Metabolism and Disposition, 2002, 30, 602-607.	1.7	87
46	Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1999, 434, 401-411.	1.4	85
47	Development of high sensitive umu test system: rapid detection of genotoxicity of promutagenic aromatic amines by Salmonella typhimurium strain NM2009 possessing high O-acetyltransferase activity. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1995, 334, 145-156.	0.4	84
48	Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica, 1986, 16, 367-378.	0.5	78
49	Comparison of rates of enzymic oxidation of aflatoxin B1, aflatoxin G1, and sterigmatocystin and activities of the epoxides in forming guanyl-N7 adducts and inducing different genetic responses. Chemical Research in Toxicology, 1989, 2, 114-122.	1.7	76
50	Electron Transport Pathway for a Streptomyces Cytochrome P450. Journal of Biological Chemistry, 2007, 282, 17486-17500.	1.6	73
51	Specificity of 17Î²-oestradiol and benzo[Î±]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica, 2001, 31, 163-176.	0.5	72
52	Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2001, 492, 81-90.	0.9	71
53	The <i>CYP3A4</i> intron 6 C>T polymorphism (<i>CYP3A4*22</i>) is associated with reduced CYP3A4 protein level and function in human liver microsomes. Journal of Toxicological Sciences, 2013, 38, 349-354.	0.7	70
54	Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochemical Pharmacology, 1996, 52, 301-309.	2.0	69

#	Article	IF	Citations
55	Comparison of the DNA-alkylating properties and mutagenic responses of a series of S-(2-haloethyl)-substituted cysteine and glutathione derivatives. Biochemistry, 1990, 29, 10342-10350.	1.2	68
56	Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics and Genomics, 2003, 13, 689-695.	5.7	67
57	Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxicity assays. Carcinogenesis, 1994, 15, 2523-2529.	1.3	66
58	Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5 enzymes. Archives of Biochemistry and Biophysics, 2005, 435, 207-216.	1.4	66
59	Highly sensitiveumu test system for the detection of mutagenic nitroarenes inSalmonella typhimurium NM3009 having high O-acetyltransferase and nitroreductase activities. Environmental and Molecular Mutagenesis, 1993, 21, 357-364.	0.9	65
60	Involvement of Cytochrome P450, Glutathione S-Transferase, and Epoxide Hydrolase in the Metabolism of Aflatoxin B 1 and Relevance to Risk of Human Liver Cancer. Environmental Health Perspectives, 1996, 104, 557.	2.8	63
61	CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Archives of Toxicology, 2000, 73, 532-539.	1.9	60
62	Metabolic activation of environmental carcinogens and mutagens by human liver microsomes. Biochemical Pharmacology, 1988, 37, 459-465.	2.0	58
63	Different Mechanisms for Inhibition of Human Cytochromes P450 1A1, 1A2, and 1B1 by Polycyclic Aromatic Inhibitors. Chemical Research in Toxicology, 2007, 20, 489-496.	1.7	58
64	Aflatoxin B1 8,9-Epoxide Hydrolysis in the Presence of Rat and Human Epoxide Hydrolase. Chemical Research in Toxicology, 1997, 10, 672-676.	1.7	57
65	Activation of 3,4,3â€²,4â€²-tetrachlorobiphenyl to protein-bound metabolites by rat liver microsomal cytochrome P-448-containing monooxygenase system. Toxicology and Applied Pharmacology, 1983, 70, 486-493.	1.3	56
66	Construction of a Human Cytochrome P450 1A1:Rat NADPHâ€“Cytochrome P450 Reductase Fusion Protein cDNA and Expression inEscherichia coli,Purification, and Catalytic Properties of the Enzyme in Bacterial Cells and after Purification. Archives of Biochemistry and Biophysics, 1996, 330, 48-58.	1.4	56
67	Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomes. Carcinogenesis, 1995, 16, 2167-2170.	1.3	55
68	Expression of Cytochrome P450 3A7 inEscherichia coli:Effects of 5â€² Modification and Catalytic Characterization of Recombinant Enzyme Expressed in Bicistronic Format with NADPH-Cytochrome P450 Reductase. Archives of Biochemistry and Biophysics, 1997, 346, 81-90.	1.4	54
69	Characterization of (??)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics and Genomics, 2001, 11, 143-156.	5.7	54
70	Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescencein situ hybridization. Japanese Journal of Human Genetics, 1992, 37, 133-138.	0.8	53
71	Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. Biomedical Applications, 1999, 721, 13-19.	1.7	53
72	Metabolic Activation of Polycyclic Aromatic Hydrocarbons and Aryl and Heterocyclic Amines by Human Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology, 2013, 26, 529-537.	1.7	52

#	Article	IF	Citations
73	Inhibition of Carcinogen-Activating Cytochrome P450 Enzymes by Xenobiotic Chemicals in Relation to Antimutagenicity and Anticarcinogenicity. Toxicological Research, 2017, 33, 79-96.	1.1	45
74	Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology.. Environmental Health Perspectives, 1992, 98, 75-80.	2.8	43
75	Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7Î±- and coumarin 7-hydroxylations. Biochemical Pharmacology, 1994, 48, 1524-1527.	2.0	43
76	Sex Differences in the Metabolism of (+)- and (â^')-Limonene Enantiomers to Carveol and Perillyl Alcohol Derivatives by Cytochrome P450 Enzymes in Rat Liver Microsomes. Chemical Research in Toxicology, 2002, 15, 15-20.	1.7	43
77	Species Differences in the Metabolism of (+)- and (â^')-Limonenes and their Metabolites, Carveols and Carvones, by Cytochrome P450 Enzymes in Liver Microsomes of Mice, Rats, Guinea Pigs, Rabbits, Dogs, Monkeys, and Humans. Drug Metabolism and Pharmacokinetics, 2002, 17, 507-515.	1.1	39
78	Reverse Type I Binding Spectra of Human Cytochrome P450 1B1 Induced by Flavonoid, Stilbene, Pyrene, Naphthalene, Phenanthrene, and Biphenyl Derivatives That Inhibit Catalytic Activity: A Structureâ^'Function Relationship Study. Chemical Research in Toxicology, 2009, 22, 1325-1333.	1.7	39
79	Activation and Inactivation of Carcinogenic Dihaloalkanes and Other Compounds by Glutathione S-Transferase 5-5 in Salmonella typhimurium Tester Strain NM5004. Chemical Research in Toxicology, 1996, 9, 333-340.	1.7	37
80	A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5â€“5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system. Carcinogenesis, 1996, 17, 297-302.	1.3	37
81	Molecular modelling of human CYP1B1 substrate interactions and investigation of allelic variant effects on metabolism. Chemico-Biological Interactions, 2003, 145, 281-295.	1.7	37
82	Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes. Carcinogenesis, 1993, 14, 1271-1278.	1.3	36
83	Contributions of human liver cytochrome P450 enzymes to the N-oxidation of 4,4â€²-methylene-bis(2-chloroaniline). Carcinogenesis, 1992, 13, 217-222.	1.3	35
84	Development of a new genotoxicity test system with Salmonella typhimurium OY1001/1A2 expressing human CYP1A2 and NADPHâ€“P450 reductase. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 442, 113-120.	0.9	35
85	Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1B1 in Inhibiting Catalytic Activity. Chemical Research in Toxicology, 2008, 21, 2313-2323.	1.7	34
86	Twenty One Novel Single Nucleotide Polymorphisms (SNPs) of the CYP2A6 Gene in Japanese and Caucasians. Drug Metabolism and Pharmacokinetics, 2002, 17, 482-487.	1.1	32
87	Metabolic activation of [14C] polychlorinated biphenyl mixtures by rat liver microsomes. Bulletin of Environmental Contamination and Toxicology, 1976, 16, 25-32.	1.3	31
88	A sensitive umu test system for the detection of mutagenic nitroarenes in Salmonella typhimurium NM1011 having a high nitroreductase activity. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1992, 272, 91-99.	0.4	31
89	ROLES OF HUMAN CYP2A6 AND 2B6 AND RAT CYP2C11 AND 2B1 IN THE 10-HYDROXYLATION OF (â€“)-VERBENONE BY LIVER MICROSOMES. Drug Metabolism and Disposition, 2003, 31, 1049-1053.	1.7	31
90	Binding of Diverse Environmental Chemicals with Human Cytochromes P450 2A13, 2A6, and 1B1 and Enzyme Inhibition. Chemical Research in Toxicology, 2013, 26, 517-528.	1.7	31

#	Article	IF	Citations
91	Phospholipase D Activity of Cytochrome P450 in Human Liver Endoplasmic Reticulum. Archives of Biochemistry and Biophysics, 1999, 367, 81-88.	1.4	29
92	Spectral Modification and Catalytic Inhibition of Human Cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by Four Chemopreventive Organoselenium Compounds. Chemical Research in Toxicology, 2011, 24, 1327-1337.	1.7	26
93	Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1992, 272, 183-192.	0.4	24
94	Use of genetically engineeredSalmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase and bacterialO-acetyltransferase in SOS/umu assay. Environmental and Molecular Mutagenesis, 2000, 36, 121-126.	0.9	24
95	Understanding electron transport systems of Streptomyces cytochrome P450. Biochemical Society Transactions, 2006, 34, 1183-1185.	1.6	24
96	Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2â€²,5â€²-Tetrachlorobiphenyl. Drug Metabolism and Disposition, 2016, 44, 1899-1909.	1.7	24
97	Comparative studies on distribution and covalent tissue binding of 2,4,2?,4?- and 3,4,3?,4?-tetrachlorobiphenyl isomers in the rat. Archives of Toxicology, 1984, 55, 182-185.	1.9	23
98	Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes. Biochemical Pharmacology, 1994, 47, 1957-1963.	2.0	21
99	Structureâ€“Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology, 2016, 29, 1029-1040.	1.7	21
100	Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes. Carcinogenesis, 1991, 12, 133-139.	1.3	20
101	Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13. Xenobiotica, 2016, 46, 211-224.	0.5	20
102	Mutagenic activation of aflatoxin B1 by pulmonary, renal, and hepatic cytochrome P450s from rats. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 269, 231-236.	0.4	19
103	Inhibition of mono-oxygenase activities by 1,1,1-trichloropropene 2,3-oxide, an inhibitor of epoxide hydrase, in rat liver microsomes. Biochemical Pharmacology, 1979, 28, 1777-1781.	2.0	18
104	Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 284, 233-241.	0.4	18
105	Fluorescencein situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1. Japanese Journal of Human Genetics, 1994, 39, 337-343.	0.8	17
106	Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 2015, 28, 268-278.	1.7	17
107	Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.. Journal of Toxicological Sciences, 1996, 21, 215-226.	0.7	16
108	Characterization of liver microsomal 7-ethoxycoumarin O -deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. Archives of Toxicology, 2000, 74, 372-378.	1.9	16

#	Article	IF	Citations
109	Roles of NADPH-P450 Reductase in the O-Deethylation of 7-Ethoxycoumarin by Recombinant Human Cytochrome P450 1B1 Variants in Escherichia coli. Protein Expression and Purification, 2000, 20, 73-80.	0.6	15
110	Activation of aminophenylnorharman, aminomethylphenylnorharman and aminophenylharman to genotoxic metabolites by human N-acetyltransferases and cytochrome P450 enzymes expressed in Salmonella typhimurium umu tester strains. Mutagenesis, 2006, 21, 411-416.	1.0	15
111	Cytochrome P450 2A6 and other human P450 enzymes in the oxidation of flavone and flavanone. Xenobiotica, 2019, 49, 131-142.	0.5	15
112	A convenient assay for mephenytoin 4-hydroxylase activity of human liver microsomal cytochrome P-450. Analytical Biochemistry, 1985, 147, 174-179.	1.1	14
113	Activation of Carcinogens by Human Liver Cytochromes P-450. , 1990, 53, 381-396.		14
114	Activation of trans-l,2-dihydro-l,2-dihydroxy-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis, 1994, 15, 465-470.	1.3	13
115	Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants. Xenobiotica, 2018, 48, 565-575.	0.5	13
116	Metabolic deactivation of furylfuramide by cytothrome P450 in human and liver microsomes. Carcinogenesis, 1990, 11, 103-110.	1.3	12
117	Cytochrome P450 Reconstitution Systems. , 1998, 107, 85-94.		12
118	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology, 2019, 32, 1268-1280.	1.7	11
119	Activation of Toxic Chemicals by Cytochrome P450 Enzymes. Advances in Experimental Medicine and Biology, 1996, 387, 7-15.	0.8	11
120	Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica, 2019, 49, 791-802.	0.5	10
121	Cytochrome P-450 Oxidations and the Generation of Biologically Reactive Intermediates. Advances in Experimental Medicine and Biology, 1991, 283, 1-11.	0.8	10
122	Cytochrome P450 Reconstitution Systems. , 2006, 320, 61-72.		9
123	Lack of correlation between formation of reactive metabolites and thymic atrophy caused by 3, 4, 3?, 4?-tetrachlorobiphenyl in C57BL/6N mice. Archives of Toxicology, 1987, 59, 301-306.	1.9	8
124	Possible occurrence of P450 related to P450 HFLb in extrahepatic tissues of human fetuses and its contribution to metabolic activation of promutagens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 310, 73-77.	0.4	8
125	Preference forO-demethylation reactions in the oxidation of 2â€²-, 3â€²-, and 4â€²-methoxyflavones by human cytochrome P450 enzymes. Xenobiotica, 2020, 50, 1158-1169.	0.5	8
126	Interaction of 3,4,3?,4?-tetrachlorobiphenyl metabolites formed by cytochrome P-450 in vitro with rat erythrocytes. Archives of Toxicology, 1985, 58, 20-26.	1.9	7

#	Article	IF	Citations
127	Roles of cytochrome P450 2A6 in the oxidation of flavone, 4â€²-hydroxyflavone, and 4â€²-, 3â€²-, and 2â€²-methoxyflavones by human liver microsomes. Xenobiotica, 2021, 51, 995-1009.	0.5	6
128	High-performance liquid chromatographic method for the determination of (â˜)-verbenone 10-hydroxylation catalyzed by rat liver microsomes. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 793, 291-296.	1.2	5
129	Nicotinamide N-oxide formation by rat liver microsomes. Biochemical Pharmacology, 1983, 32, 934-936.	2.0	4
130	Liquid chromatography-tandem mass spectrometry analysis of oxidation of 2â€²-, 3â€²-, 4â€²- and 6-hydroxyflavanones by human cytochrome P450 enzymes. Xenobiotica, 2021, 51, 139-154.	0.5	4
131	Use of heterologously-expressed cytochrome P450 and glutathione transferase enzymes in toxicity assays. Toxicology, 2002, 181-182, 261-264.	2.0	3
132	O I.4 Roles of human cytochrome P450s 1A1, 1A2, 1B1, 2E1, and 3A4/5/7 in the activation of environmental procarcinogens and promutagens. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 379, S6.	0.4	2
133	AFLATOXIN B1 OXIDATION BY HUMAN CYTOCHROME P450s. Journal of Toxicological Sciences, 1998, 23, 132-135.	0.7	2
134	Comparison of rates of enzymic oxidation of aflatoxin B1, aflatoxin G1, and sterigmatocystin and activities of the epoxides in forming guanyl-N7 adducts and inducing different genetic responses [Erratum to document cited in CA110(23):207559z]. Chemical Research in Toxicology, 1989, 2, 272-272.	1.7	1
135	Oxidation of 3Â´-methoxyflavone, 4Â´-methoxyflavone, and 3Â´,4Â´-dimethoxyflavone and their derivatives having 5,7-dihydroxyl moieties by human cytochromes P450 1B1 and 2A13. Xenobiotica, 2022, , 1-41.	0.5	1
136	OMEPRAZOLE HYDROXYLATION BY CYP2C19 AND CYP3A4: PREDICTION TOWARDS HUMAN LIVER ACTIVITIES USING THE DATA OF RECOMBINANT P450 ENZYMES. Drug Metabolism and Pharmacokinetics, 1997, 12, 120-121.	0.0	0
137	Variations in contents of liver microsomal cytochrome P450 isofoms and activities of drug oxidations in humans. Drug Metabolism and Pharmacokinetics, 1999, 14, 78-79.	0.0	0
138	Inhibition of Carcinogen-Activating Cytochrome P450 Enzymes by Xenobiotic Chemicals in Relation to Antimutagenicity and Anticarcinogenicity. Toxicological Research, 2017, 33, 79-96.	1.1	0